Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma
Standard
Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma : results from a systematic literature review and network meta-analysis. / Ramasamy, Karthik; Dhanasiri, Sujith; Thom, Howard; Buchanan, Vanessa; Robinson, Suzanne; D'Souza, Vijay K; Weisel, Katja.
in: LEUKEMIA LYMPHOMA, Jahrgang 61, Nr. 3, 03.2020, S. 668-679.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma
T2 - results from a systematic literature review and network meta-analysis
AU - Ramasamy, Karthik
AU - Dhanasiri, Sujith
AU - Thom, Howard
AU - Buchanan, Vanessa
AU - Robinson, Suzanne
AU - D'Souza, Vijay K
AU - Weisel, Katja
PY - 2020/3
Y1 - 2020/3
N2 - Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treatments for TNE NDMM include Rd plus bortezomib (RVd) and daratumumab plus VMP (VMP + D), daratumumab plus lenalidomide and dexamethasone (D + Rd). Relative efficacy of these treatments was compared using a network meta-analysis. Eight trials identified by a systematic literature review were included in the primary analysis; hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were used. Rd was superior to other MP-based regimens for OS and PFS. There was strong evidence that, compared with Rd, both D + Rd and RVd improved PFS (HR 0.57; 95% credible interval (CrI) 0.43, 0.73 and HR 0.72; 95% CrI 0.56, 0.91, respectively). However, there was strong evidence only for RVd in respect to OS (HR 0.72; 95% CrI 0.52, 0.96).
AB - Established treatments for transplant-ineligible (TNE) patients with newly diagnosed multiple myeloma (NDMM) include melphalan and prednisone (MP) combined with either bortezomib (VMP) or thalidomide (MPT), or lenalidomide plus low-dose dexamethasone (Rd). New treatments for TNE NDMM include Rd plus bortezomib (RVd) and daratumumab plus VMP (VMP + D), daratumumab plus lenalidomide and dexamethasone (D + Rd). Relative efficacy of these treatments was compared using a network meta-analysis. Eight trials identified by a systematic literature review were included in the primary analysis; hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were used. Rd was superior to other MP-based regimens for OS and PFS. There was strong evidence that, compared with Rd, both D + Rd and RVd improved PFS (HR 0.57; 95% credible interval (CrI) 0.43, 0.73 and HR 0.72; 95% CrI 0.56, 0.91, respectively). However, there was strong evidence only for RVd in respect to OS (HR 0.72; 95% CrI 0.52, 0.96).
U2 - 10.1080/10428194.2019.1683736
DO - 10.1080/10428194.2019.1683736
M3 - SCORING: Journal article
C2 - 31709875
VL - 61
SP - 668
EP - 679
JO - LEUKEMIA LYMPHOMA
JF - LEUKEMIA LYMPHOMA
SN - 1042-8194
IS - 3
ER -